Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
REPL

REPL - Replimune Group Inc Stock Price, Fair Value and News

$7.37-0.16 (-2.12%)
Market Closed

24/100

REPL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

24/100

REPL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$6.17

Target 3M

$6.95

Target 6M

$6.55

REPL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

REPL Price Action

Last 7 days

1.5%

Last 30 days

-24.5%

Last 90 days

-28.1%

Trailing 12 Months

-47.4%

REPL RSI Chart

REPL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

REPL Valuation

Market Cap

578.1M

Price/Earnings (Trailing)

-1.86

Price/Sales (Trailing)

29.76

EV/EBITDA

-2.57

Price/Free Cashflow

-2.2

REPL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$6.17

Target 3M

$6.95

Target 6M

$6.55

REPL Fundamentals

REPL Revenue

Revenue (TTM)

19.4M

Rev. Growth (Yr)

-31.48%

Rev. Growth (Qtr)

-21.6%

REPL Earnings

Earnings (TTM)

-310.2M

Earnings Growth (Yr)

-56.63%

Earnings Growth (Qtr)

4.14%

REPL Profitability

EBT Margin

-1168.56%

Return on Equity

-117.81%

Return on Assets

-79.66%

Free Cashflow Yield

-45.43%

REPL Investor Care

Shares Dilution (1Y)

14.65%

Diluted EPS (TTM)

-3.46

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202521.1M21.1M19.4M0
202423.4M21.9M21.2M20.7M
202310.0M15.8M20.8M23.8M
20221.7M1.3M1.7M4.3M
20212.8M2.9M2.9M2.4M
20203.1M3.1M3.3M2.9M
20192.8M3.3M3.2M2.6M
20182.3M2.1M2.1M3.0M
20170000
Get all data in R, Python etc through our Historical Stock Data APIs

About Replimune Group Inc

REPL
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
 CEO
 WEBSITEreplimune.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES284

Replimune Group Inc Frequently Asked Questions

REPL is the stock ticker symbol of Replimune Group Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Replimune Group Inc is 578.13 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check REPL's fair value in chart for subscribers.

The fair value guage provides a quick view whether REPL is over valued or under valued. Whether Replimune Group Inc is cheap or expensive depends on the assumptions which impact Replimune Group Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for REPL.

As of Wed Jan 28 2026, REPL's PE ratio (Price to Earnings) is -1.86 and Price to Sales (PS) ratio is 29.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. REPL PE ratio will change depending on the future growth rate expectations of investors.